Because many transplant programs require a body mass index (BMI) below 30 to 35, weight loss associated with GLP-1 therapy may help more patients qualify for transplantation while simultaneously delaying disease progression
Its formula blends targeted probiotic strains, supportive prebiotics, and metabolic compounds to address digestion, energy, immunity, and weight management at the same time
That Novo Nordisk-funded study of almost 2,000 overweight or obese adults without diabetes also found their visceral fat the type that accumulates in the belly was reduced from baseline with semaglutide, along with their total fat mass
Youll learn what to look for on a label, why sourcing matters, and how Aspires approach ensures you get real results without putting your health at risk
GLP-1 Market Share, By End User, 2025 (%) The hospitals segment held a 19% share of the market in 2025 and is expected to grow at a CAGR of 8.4% during the projection period
Research-Use Reminder InStrips products are offered for research and analytical use only